RxDoctor Payments Data

Eric Lai, MD

Nephrology · Pleasanton, CANPI 1942592522

Payments from drug & device makers

$22,804in general payments, 2019–2025

Across 239 payments — averaging $95.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$7K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
  • Calliditas Therapeutics US Inc.$4K
  • Fresenius USA Marketing, Inc.$856
  • AstraZeneca$835
  • Amgen$495
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$12,94957%
  • Speaking & faculty fees$1,6007%
  • Travel & lodging$2,20810%
  • Food & beverage$5,87126%
  • Education$1761%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,804 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$375,188
Medicare patients
456
Services billed
2,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol69$61,121
XphozahTenapanor Hcl15$60,700
KerendiaFinerenone71$55,500
LokelmaSodium Zirconium Cyclosilicate55$44,179
JardianceEmpagliflozin53$37,742
VeltassaPatiromer Calcium Sorbitex20$23,715
TradjentaLinagliptin38$19,571
ProcritEpoetin Alfa25$15,464
RayaldeeCalcifediol12$10,150
Sevelamer Carbonate31$8,158
JanuviaSitagliptin Phosphate11$7,108
Hydralazine Hcl218$2,411
Tamsulosin Hcl167$1,597
Famotidine153$1,358
Losartan Potassium144$1,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$835$105,300124 claims
Boehringer IngelheimJardiance, Tradjenta$121$57,31391 claims
BayerKerendia$199$55,50071 claims
OPKO Pharmaceuticals, LLCRayaldee$103$10,15012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.

Other nephrology in Pleasanton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →